MichaelAPochMD

Urology • Tampa, FL

Surgical Oncology

Physician

Join to view full profile

Dr. Poch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Poch's full profile

Already have an account?

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Phone+1 813-745-8418

Fax+1 813-745-4675

Education & Training

University at Buffalo (Roswell Park Cancer Institute)Fellowship, Urologic Surgical Oncology, 2010 - 2012
Brown UniversityResidency, Urology, 2006 - 2010
Brown UniversityInternship, Transitional Year, 2005 - 2006
The Warren Alpert Medical School of Brown UniversityClass of 2005

Certifications & Licensure

FL State Medical License 2012 - 2025
NY State Medical License 2010 - 2013
American Board of Urology Urology

Clinical Trials

Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness Start of enrollment: 2009 Dec 11
Completed
Phase 2
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer Start of enrollment: 2011 Nov 25
Active, not recruiting
Not Applicable
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Start of enrollment: 2017 Feb 03
Completed
Phase 2, Phase 3
ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Start of enrollment: 2016 Sep 19
Completed
Phase 3
Clinical Trial of Green Tea Catechins in Men on Active Surveillance Start of enrollment: 2020 Aug 21
Recruiting
Phase 2
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC Start of enrollment: 2020 Oct 26
Active, not recruiting
Phase 1
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Start of enrollment: 2022 Feb 23
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Sociodemographic and Provider Based Disparities in the Management of Stage I Testicular Cancer.
Gautum Agarwal, Pranav Sharma, Oscar Valderrama, Hui-Yi Lin, Binglin Yue
Urology Practice. 2017-01-01
11 citations
Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study
Selene Rubino, Young-Chul Kim, Junmin Zhou, Jasreman Dhilon, Roger Li
World Journal of Urology. 2021-05-01
3 citations
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
Ahmet Murat Aydin, Salim K Cheriyan, Richard Reich, Ali Hajiran, Charles C Peyton
Urologic Oncology. 2022-10-01

Committees

Member, Performance Improvement & Safety Committee (PISC) 2018 - Present
Member, Surgical CPOE Optimization Committee 2018 - Present
Chair, Surgery Safety Committee 2017 - Present
Member At Large, Medical Executive Committee 2016 - 2018
Member, Patient Portal Steering Committee 2014 - 2016
Member, Revenue Cycle Committee 2014 - 2015
Member, Ethics Committee 2012 - 2013

Professional Memberships

American Urological Association - AUA
Member
American Society of Clinical Oncologists - ASCO
Member
Florida Medical Association - FMA
Member
Florida Urologic Society - FUS
Member
Society of Urologic Oncology - SUO
Member